An initiative by Medtalks, in association with Mankind Pharma to bring to you new findings from key trials, in the prevention and management of diabetes.
In this Issue 2 we will discuss about NAFLD and SGLT2 inhibitors. NAFLD is closely linked with type 2 diabetes. The role of SGLT2 inhibitors; Justification; Current trials status; Future of SGLT2i in NAFLD; Currently available drugs for NAFLD. A recent research has shown that patients with NAFLD have a higher risk of diabetes, and the more severe the disease the greater the risk.
Dr. Ambrish Mithal is an Indian endocrinologist, diabetologist and the Chairman and Head of Endocrinology and Diabetes division of Medanta, the Medicity, a super specialty hospital located at Gurgaon, Haryana. Dr. Mithal was honoured by the Government of India in 2015 with Padma Bhushan, the third highest Indian civilian award and also with Dr BC Roy Award for Best talents in encouraging the development of specialities in different branches in Medicine. Dr. Mithal has made pioneering contribution to the development of the speciality of endocrinology in India in all its aspects- academic, clinical and social and has played a key role in placing Indian endocrinology on the global map. Dr. Ambrish Mithal is the first and only Indian to receive the “Boy Frame Award” of the American Society of Bone and Mineral Research, in 2004. He also received the International Osteoporosis Foundation Health Professional Awareness award (for ISBMR) in 2005. His paper on “Global Vitamin D Status’ was awarded the Springer citation prize in 2013. He has received numerous awards from various Indian associations, including Doctor of the year (2005), “Distinguished contribution in the field of medicine”, “Medical statesman of the year” and others.